Skip to main content
Shanghai Hile Bio-Technology Co.,Ltd logo

Shanghai Hile Bio-Technology Co.,Ltd — Investor Relations & Filings

Ticker · 603718 ISIN · CNE1000022T4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603718

About Shanghai Hile Bio-Technology Co.,Ltd

http://www.hile-bio.com/

Shanghai Hile Bio-Technology Co., Ltd. specializes in the research, development, production, and distribution of veterinary biological products. The company focuses on providing comprehensive health solutions for the livestock and poultry sectors. Its core product portfolio includes a wide range of vaccines targeting major animal diseases, such as swine fever, porcine reproductive and respiratory syndrome (PRRS), foot-and-mouth disease, and various avian influenza strains. Utilizing advanced biotechnology and large-scale manufacturing processes, the company operates high-standard production facilities compliant with Good Manufacturing Practice (GMP) requirements. Hile Bio-Technology emphasizes innovation through its dedicated research and development centers, aiming to enhance animal disease prevention and control. The company serves large-scale farming enterprises and veterinary service providers, maintaining a significant presence in the animal health sector through its commitment to product quality and technical support.

Recent filings

Filing Released Lang Actions
海利生物股票交易异常波动公告
Regulatory Filings Classification · 98% confidence The document is an announcement regarding abnormal stock trading fluctuations for Shanghai Haili Biological Technology Co., Ltd., required under Shanghai Stock Exchange rules. It does not present financial statements or constitute a periodic report, nor is it a proxy, dividend, or management change notice. It is a compliance/regulatory announcement. Therefore, it is classified as Regulatory Filings (RNS).
2026-05-29 Chinese
湖南泽尔顿新材料有限公司审计报告（希会审字【2026】3909号）
Audit Report / Information Classification · 95% confidence The document is titled “审计报告” and contains an auditor’s opinion, basis of opinion, management’s responsibilities, auditor’s responsibilities, and full consolidated and parent company financial statements (balance sheet, income statement, cash flows, equity changes, notes). It is a standalone audit report issued by a registered accounting firm, not just an announcement or summary. Thus it fits the definition of an Audit Report / Information. FY 2025
2026-05-28 Chinese
陕西瑞盛生物科技有限公司拟股权收购事宜涉及的湖南泽尔顿新材料有限公司股东全部权益资产评估报告（卓信大华评报字【2026】第8755号）
M&A Activity Classification · 85% confidence The document is a comprehensive asset valuation report prepared by an appraisal firm for the purpose of a share acquisition (M&A) by Shaanxi Ruisheng Biotechnology Co., Ltd. of Hunan Zerdent New Materials Co., Ltd. It contains detailed valuation methods, financial data, legal and regulatory references, and appraisal conclusions. This is not an earnings release, annual report, audit report, or investor presentation, but rather a detailed valuation report used in merger and acquisition transactions. Therefore, it fits the “M&A Activity” category (Code: TAR).
2026-05-28 Chinese
海利生物关于为控股子公司提供担保额度的公告
Regulatory Filings Classification · 75% confidence The document is a formal stock exchange announcement by Shanghai Haili Biotech Co., Ltd. regarding the Board’s approval of a guarantee limit for its holding subsidiary. It provides detailed guarantee amounts, risk indicators, board resolutions, and internal decision procedures. It does not present any financial statements as an annual or interim report, nor is it an earnings release, dividend notice, or management change announcement. It’s a required compliance announcement under exchange rules about contingent guarantees and does not fit any of the more specific categories (e.g., CAP deals with capital raising or financing structure changes, but here the company is not issuing debt or equity, only providing a guarantee). Therefore, it falls under the general regulatory announcements category (RNS).
2026-05-28 Chinese
海利生物第五届董事会第二十一次会议决议公告
Regulatory Filings Classification · 65% confidence The document is a Chinese listed company’s public announcement of board of directors’ meeting resolutions, detailing meeting logistics, deliberated proposals (e.g., stock incentive plan outcomes, share cancellations, capital amendment, related‐party transactions, M&A, guarantees) and voting results. It is not an AGM material, earnings release, financial report, or a director change notice. It is a regulatory disclosure required by the stock exchange but does not fit any of the highly specific categories (e.g., change in board composition, dividend notice, M&A filing). As such, it is best classified under the fallback “Regulatory Filings” (RNS).
2026-05-28 Japanese
海利生物全资子公司向关联方采购原材料暨日常关联交易公告
Regulatory Filings Classification · 85% confidence The document is an official exchange announcement detailing a subsidiary’s daily related‐party raw material purchases, including board approvals, related party definitions, pricing, and impact. It is not a full financial report (e.g., 10‐K/IR), not a dividend or share issuance notice, and does not fit other specific categories. It is a general compliance/regulatory announcement (“关联交易公告”), so it falls under the fallback Regulatory Filings (RNS).
2026-05-28 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.